FTC Lawsuit adds another dimension to the story

Research evidence excerpt

FTC Lawsuit adds another dimension to the story

Idea

July 30, 2026 04:01 AM GMT

Morgan Stanley & Co. LLCMHims & Hers Health Inc | North America Craig Hettenbach

Equity Analyst

FTC Lawsuit adds another Craig.Hettenbach@morganstanley.comJialin Jin +1 212 761-6435

Research Associate

Jay.Jin@morganstanley.com +1 212 761-3913

dimension to the story Erin Wright

Erin.Wright1@morganstanley.com +1 212 761-6137

On the heels of enthusiasm for the Peptides opportunity, this Linda Bolduc

news weighed heavily the stock. While Hims was quick to Equity Analyst

Linda.Bolduc@morganstanley.com +1 617 856-8009

respond by questioning the merits of the suit, it likely serves as Michelle Foley

an overhang into the company's earnings on August 10. We ResearchMichelle.Foley@morganstanley.comAssociate +1 212 761-4056

remain Equal-weight with modest downside to PT. Derek Gross

What Happened: The stock sold off ~15% yesterday (vs. Nasdaq -1.7%) on elevated Derek.Gross@morganstanley.com +1 212 761-2455

Katherine A Bennorth

volume after news that the FTC, Utah and LA County have sued Hims for allegedly Research Associate

misleading consumers about its products, sharing data with Meta and Snap (both Katie.A.Bennorth@morganstanley.com +1 212 761-3753

covered by Brian Nowak), enrolling consumers in recurring subscription plans

Hims & Hers Health Inc (HIMS.N, HIMS US)

quickly after questionnaire intake forms were completed and making difficult to

Healthcare Technology | United States of America

cancel subscriptions. For background, the FTC has been investigating the company Stock Rating Equal-weight

for over a year regarding its business practices following consumer complaints Industry View In-Line

Price target $21.00

about cancelation practices. Shr price, close (Jul 29, 2026) $25.00